FOR IMMEDIATE RELEASE

For more information contact:
Sandy Fewkes (media contact)
MindWrite Communications, Inc.
+1 408 224 4024
sandy@mind-write.com

FEI
Jason Willey (investors and analysts)
Sr. Director, Investor Relations & Corporate Development
+1 503 726 2533
jason.willey@fei.com

Nature Methods Names Cryo-Electron Microscopy "Method of the Year 2015"

FEI, an early pioneer of Cryo-EM, has made many enabling technological innovations.

Hillsboro, Ore./January 19, 2016—FEI (NASDAQ: FEIC) is pleased to announce that cryo-electron microscopy (cryo-EM) has been named "Method of the Year 2015" by *Nature Methods*, in a Special Feature of the January 2016 issue: http://www.nature.com/nmeth/focus/moy2015/index.html (doi:10.1038/nmeth.3730).

"State-of-the-art cryo-electron microscopes are impacting biomedical research like never before, delivering atomic-level, three-dimensional structures of medically-important proteins to university and pharmaceutical company scientists with unprecedented speed and accuracy," said Professor Stephen K. Burley, M.D., D. Phil. Director of the RCSB Protein Data Bank and Distinguished Professor of Chemistry and Chemical Biology at Rutgers, The State University of New Jersey. "Over the next few years, these new instruments will enable the power of structure-guided drug discovery to be brought to bear on entirely new classes of disease-causing proteins, particularly those responsible for neurological and psychiatric illnesses where there remain enormous, unmet medical needs," added Burley.

"*Nature Methods*' recognition of cryo-EM as 'Method of the Year 2015' is an extremely prestigious award within the life science research community," said Peter Fruhstorfer, vice president and general manager of the Life Sciences business, FEI. "We are deeply gratified to know that our investments in developing and commercializing the technique are paying important dividends in scientific advancements that have the potential to benefit the well-being of all."

Biologists use cryo-EM to study the structure and function of cells, viruses and protein assemblies at the molecular, sub-nanometer scale. Recent technological advancements in the microscope design and imaging hardware, along with enhanced image processing and automation, have helped to catapult the technique's success. Many leading scientists have recently adopted the technique as one of the most critical tools in their laboratory. Established methods for structure determination, such as x-ray crystallography and nuclear magnetic resonance spectroscopy, are now routinely integrated with cryo-EM density maps to achieve atomic-resolution models of complex, dynamic molecular assemblies.

Fruhstorfer adds, "FEI pioneered cryo-EM with its introduction of the Titan Krios™ transmission electron microscope in 2008. Since then, we have continued to make advancements in the technology and have partnered with several leading scientists to develop a sample preparation and imaging workflow that has potentially game changing power in structural and cellular biology."

More information about cryo-EM can be found at http://www.fei.com/life-sciences/.

About FEI
FEI Company (Nasdaq: FEIC) designs, manufactures and supports a broad range of high-performance microscopy workflow solutions that provide images and answers at the micro-, nano- and picometer scales. Its innovation and leadership enable customers in industry and science to increase productivity and make breakthrough discoveries. Headquartered in Hillsboro, Ore., USA, FEI has over 2,800 employees and sales and service operations in more than 50 countries around the world. More information can be found at: www.fei.com.

FEI Safe Harbor Statement
This news release contains forward-looking statements that include statements regarding the performance capabilities and benefits of the Titan Krios TEM and cryo-EM workflow solution. Factors that could affect these forward-looking statements include but are not limited to our ability to manufacture, ship, deliver and install the tools, solutions or software

as expected; failure of the product or technology to perform as expected; unexpected technology problems and challenges; changes to the technology; the inability of FEI, its suppliers or project partners to make the technological advances required for the technology to achieve anticipated results; and the inability of the customer to deploy the tools or develop and deploy the expected new applications. Please also refer to our Form 10-K, Forms 10-Q, Forms 8-K and other filings with the U.S. Securities and Exchange Commission for additional information on these factors and other factors that could cause actual results to differ materially from the forward-looking statements. FEI assumes no duty to update forward-looking statements.

# # #